In crowded fields like oncology, most companies flock to a few validated ideas, like kids chasing a soccer ball. Delpha Therapeutics' CEO Kevin Marks argues the real opportunity lies in pioneering novel biology in the wide-open parts of the field, creating a strategic advantage and potential scarcity effect.
The core job of a scientist isn't knowing facts, but figuring out what's unknown. This problem-solving 'toolbox'—how to think, act, and work with teams to tackle new problems—is directly transferable to the CEO role, enabling leaders to navigate unfamiliar domains like corporate finance or legal structures.
A CEO's role is seeing the same company through the different lenses of various stakeholders (investors, lawyers, scientists). Success requires learning the unique 'language' of each group—their incentives and communication styles—to effectively translate the company's vision and value proposition for each audience.
Developing a new medicine is 'the toughest team sport,' requiring hundreds of people across diverse disciplines over many years. In this context, culture isn't a perk; it's the fundamental 'glue' that enables these disparate teams to work in concert and succeed. Without it, even the best individual players will fail.
Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.
While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.